Roche
NEWS
50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
The company presented the data at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
This week, Roche said it extended its tender-offer period for outstanding shares of Spark to Oct. 1 from Sept. 3.
Genentech said Phase III data from the BLOCKSTONE study showed that an individual treated with Xofluza after being exposed to the flu by an infected household member, reduced the risk of developing the flu by 86% compared to placebo.
Biopharma companies strengthen their senior leadership teams and boards of directors with this week’s appointments.
Sandra Horning, Roche’s chief medical officer and head of global product development, will retire from the company at the end of the year, leaving some big shoes to fill.
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
JOBS
IN THE PRESS